he purpose of this report was to update the 2006 International League Against Epilepsy (ILAE) report and identify the level of evidence for long-term efficacy or effectiveness for antiepileptic drugs (AEDs) as initial monotherapy for patients with newly diagnosed or untreated epilepsy. All applicable articles from July 2005 until March 2012 were identified, evaluated, and combined with the previous ysis (Glauser et al., 2006) to provide a comprehensive update.
The prior ysis methodology was utilized with three modifications: (1) the detectable noninferiority boundary approach was dropped and both failed superiority studies and prespecified noninferiority studies were yzed using a noninferiority approach, (2) the definition of an adequate comparator was clarified and now includes an absolute minimum point estimate for efficacy/effectiveness, and (3) the relationship table between clinical trial ratings, level of evidence, and conclusions no longer includes a recommendation column to reinforce that this review of efficacy/evidence for specific seizure types does not imply treatment recommendations.
This evidence review contains one clarification: The commission has determined that class I superiority studies can be designed to detect up to a 20% absolute (rather than relative) difference in the point estimate of efficacy/effectiveness between study treatment and comparator using an intent-to-treat ysis. Since July, 2005, three class I randomized controlled trials (RCT) and 11 class III RCTs he been published. The combined ysis (1940-2012) now includes a total of 64 RCTs (7 with class I evidence, 2 with class II evidence) and 11 meta-yses.
New efficacy/effectiveness findings include the following: levetiracetam and zonisamide he level A evidence in s with partial onset seizures and both ethosuximide and valproic acid he level A evidence in children with childhood absence epilepsy.
There are no major changes in the level of evidence for any other subgroup. Levetiracetam and zonisamide join carbamazepine and phenytoin with level A efficacy/effectiveness evidence as initial monotherapy for s with partial onset seizures. Although ethosuximide and valproic acid now he level A efficacy/effectiveness evidence as initial monotherapy for children with absence seizures, there continues to be an alarming lack of well designed, properly conducted epilepsy RCTs for patients with generalized seizures/epilepsies and in children in general.
These findings reinforce the need for multicenter, multinational efforts to design, conduct, and yze future clinically relevant adequately designed RCTs. When selecting a patient's AED, all relevant variables and not just efficacy and effectiveness should be considered.
查看信道地址
下一页:隐源性癫痫死亡率有所增加
- 2022-04-272013年国际抗癫痫联合会抗癫痫止痛使用指南
- 2022-04-25卒中后癫痫首选口服有哪些?解答卒中后癫痫的4大问题
- 2019-04-20颞叶癫痫病人的寿命长吗
- 控制癫痫患者再次抽搐,不包括可选药物?
- 癫痫治愈费用
- 癫痫患者手术评估新型工具
- 手术学习:颅内脊索瘤内镜下三脑室入路治疗
- 癫痫治疗障碍仍难以克服
- 抗癫痫药物预防新发癫痫:任重而道远
- FDA批准Aptiom用于治疗患者癫痫发作
- 综述:癫痫持续状态诊治最新进展
- 预测癫痫患者再入院风险
- FDA批准开浦兰治疗1个月至4岁癫痫儿童
- 癫痫发作的症状是什么?
- 癫痫猝死:凶手是谁?
- 癫痫患者应多喝牛奶,饮食疗法公开
- Neurology:颅脑损伤增加了迟发性癫痫的风险,高损伤频率、重伤、老年人尤其是
- 脑梗死的症状是什么有这些前兆要谨慎
- 不注意这些问题,吃多少药都没用!
- 上海率先探索异地就医门诊费直接结算
- 黑芝麻的营养价值 吃黑芝麻的好处
- 北京癫痫医院治疗费用
- 癫痫发作对中风患者静脉溶栓的长期转移有效
- Circ Ep:左室肥厚高血压患者新发房颤增加SCD风险
- 癫痫患者春节期间的饮食问题
- 月经期间要注意 有些药物和食物不能食用
- 常见的癫痫病因有哪些?
- 治疗法隐源性癫痫病要多少钱
- 放射治疗癫痫病方法哪种最有效
- 疗程儿童癫痫病是什么方法比较好呢
- 治疗癫痫病民间小儿
- 怎么用科学的作法治疗癫痫病
- 帕金森氏症病小发作症状 这些症状就是帕金森氏症小发作
- 癫痫病的病因具体分作哪些
- 研究课题称猪肉绦虫患者的癫痫由p物质引起
- 有助癫痫病治疗的日常习惯
- 大脑缺氧 大脑缺氧的征状
- 科学家告诉你癫痫病的治疗好方法
- 部位癫痫病如何治疗
- 老年人得了癫痫病有什么副作用
- 癫痫病症状 怎样卫生癫痫病人
- 癫痫病的性疾病是哪些因素影响的呢
- 癫痫病频繁高烧怎么办